India’s Biocon Wins 1st Biosimilar Approval Of Herceptin; Will Launch Before March 2014
This article was originally published in PharmAsia News
Executive Summary
As the decks are cleared for an India launch of trastuzumab, Biocon and its global partner Mylan will be watched closely by both local and global competitors. The market impact in India will be most significant in terms of price, and it will test if Roche has played its cards right by aligning with local company Emcure.